# EDGAR Filing Document

**Accession Number:** 0000839087
**File Stem:** 0001213900-26-053854
**Filing Date:** 2026-5
**Character Count:** 4978
**Document Hash:** e8964434af69a97ef5689b15b6304cf6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-053854.hdr.sgml**: 20260508

**ACCESSION NUMBER**: 0001213900-26-053854

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260504

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260508

**DATE AS OF CHANGE**: 20260508

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VASO Corp
- **CENTRAL INDEX KEY:** 0000839087
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 112871434
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-18105
- **FILM NUMBER:** 26958109

**BUSINESS ADDRESS:**
- **STREET 1:** 137 COMMERCIAL STREET, STE. 200
- **CITY:** PLAINVIEW
- **STATE:** NY
- **ZIP:** 11803
- **BUSINESS PHONE:** 516-997-4600

**MAIL ADDRESS:**
- **STREET 1:** 137 COMMERCIAL STREET, STE. 200
- **CITY:** PLAINVIEW
- **STATE:** NY
- **ZIP:** 11803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VASOMEDICAL, INC
- **DATE OF NAME CHANGE:** 20120606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VASOMEDICAL INC
- **DATE OF NAME CHANGE:** 19950517

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FUTURE MEDICAL PRODUCTS INC /DE/
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):

<u>May 4, 2026</u>

**VASO CORPORATION**

**(Exact Name of Registrant as Specified in Charter)**

---

| | | |
|:---|:---|:---|
| Delaware | 0-18105 | 11-2871434 |
| **(State or Other Jurisdiction of Incorporation)** | **(Commission File Number)** | **(I.R.S. Employer Identification No.)** |

---

---

| |
|:---|
| 137 Commercial St., Suite 200, Plainview, New York 11803 |
| **(Address of Principal Executive Offices and Zip Code)** |
| (516) 997-4600 |
| **Registrant's Telephone Number, Including Area Code** |
| Not Applicable |
| **(Former Name or Former Address, if Changed Since Last Report)** |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on which Registered** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Exchange Act (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02(e)**

On May 4, 2026, Vaso Corporation ("Vaso") entered into an agreement with Peter Castle, President of VasoTechnology Inc., a wholly-owned subsidiary of Vaso. The agreement provides an opportunity to earn an incentive payment for Mr. Castle's participation in helping Vaso achieve specified corporate outcomes relating to potential strategic initiatives (the "Objectives"). If the Objectives are achieved within the time period specified in the agreement, and subject to his continued compliance with the agreement, Mr. Castle will be paid $175,000. Otherwise, he will not receive any portion of the incentive amount.

**Item 9.01 Exhibits**

<u>Exhibit No.</u> <u>Description</u> <br> 104 Cover page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 8, 2026

---

| | |
|:---|:---|
| **VASO CORPORATION** | **VASO CORPORATION** |
| By: | /s/ Jun Ma |
| Name: | Jun Ma |
| Title: | Chief Executive Officer and President |

---